Cardiovascular disease, SCI and exercise: unique risks and focused countermeasures

References

• Nash MS. Cardiovascular disease after spinal cord injuries. Top Spinal Cord Inj Rehabil 2009;14:1–109.
   Google Scholar
• Bauman WA, Spungen AM. Coronary heart disease in individuals with spinal cord injury: assessment of risk factors. Spinal Cord 2008;46:466–476.
   PubMed Web of Science ®Google Scholar
• Myers J, Lee M, Kiratli J. Cardiovascular disease in spinal cord injury: an overview of prevalence, risk, evaluation, and management. Am J Phys Med Rehabil 2007;86:142–152.
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421.
   PubMed Web of Science ®Google Scholar
• Cowan RE, Malone LA, Nash MS. EXERCISE is Medicine©: exercise prescription after SCI to manage CVD risk factors. Top SCI Rehabil 2009;14:69–83.
   Google Scholar
• Nash MS, Mendez AJ. A guideline-driven assessment of need for cardiovascular disease risk intervention in persons with chronic paraplegia. Arch Phys Med Rehabil 2007;88:751–757.
   PubMed Web of Science ®Google Scholar
• Bauman WA, Spungen AM, Zhong YG, Rothstein JL, Petry C, Gordon SK. Depressed serum high density lipoprotein cholesterol levels in veterans with spinal cord injury. Paraplegia 1992;30:697–703.
   PubMedGoogle Scholar
• Bauman WA, Spungen AM, Raza M, Rothstein J, Zhang RL, Zhong YG, Tsuruta M, Shahidi R, Pierson RN, Wang J, Gordon SK. Coronary artery disease: metabolic risk factors and latent disease in individuals with paraplegia. Mt Sinai J Med 1992;59:163–168.
   PubMed Web of Science ®Google Scholar
• Brenes G, Dearwater S, Shapera R, LaPorte RE, Collins E. High density lipoprotein cholesterol concentrations in physically active and sedentary spinal cord injured patients. Arch Phys Med Rehabil 1986;67:445–450.
   PubMed Web of Science ®Google Scholar
• Pietrobelli A, Lee RC, Capristo E, Deckelbaum RJ, Heymsfield SB. An independent, inverse association of high-density-lipoprotein- cholesterol concentration with nonadipose body mass. Am J Clin Nutr 1999;69:614–620.
   PubMed Web of Science ®Google Scholar
• Vrentzos GE, Papadakis JA, Ganotakis ES, Paraskevas KI, Gazi IF, Tzanakis N, Nair DR, Mikhailidis DP. Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular disease. Int J Clin Pract 2007;61:1643–1653.
   PubMed Web of Science ®Google Scholar
• D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–753.
   PubMed Web of Science ®Google Scholar
• Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105:310–315.
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351–364.
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237–1245.
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ. Conclusions from the VA-HIT study. Am J Cardiol 2000;86:543–544.
   PubMed Web of Science ®Google Scholar
• Brown AS. Primary prevention of coronary heart disease: implications of the Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). Curr Cardiol Rep 2000;2:439–444.
   PubMedGoogle Scholar
• Emmons RR, Cirnigliaro CM, Moyer JM, Garber CE, Kirshblum SC, Spungen AM, Bauman WA. Exaggerated postprandial triglyceride response identified in individuals with spinal cord injury with cardiac risk factors. Med Sci Sports Exerc. 200941404–405.
   Google Scholar
• Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473–485.
   PubMed Web of Science ®Google Scholar
• Nash MS, DeGroot J, Martinez-Arizala A, Mendez AJ. Evidence for an exaggerated postprandial lipemia in chronic paraplegia. J Spinal Cord Med 2005;28:320–325.
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340:115–126.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135–1143.
   PubMed Web of Science ®Google Scholar
• Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003;92:17K–22K.
   PubMed Web of Science ®Google Scholar
• Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004;44:6–11.
   PubMed Web of Science ®Google Scholar
• Granger JP. Inflammatory cytokines, vascular function, and hypertension. Am J Physiol Regul Integr Comp Physiol 2004;286:989–990.
   Web of Science ®Google Scholar
• Ito T, Ikeda U. Inflammatory cytokines and cardiovascular disease. Curr Drug Targets Inflamm Allergy 2003;2:257–265.
   PubMedGoogle Scholar
• Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, Kitajima S, Morimoto M, Watanabe T, Asada Y, Chen YE, Fan J. C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol 2005;167:1139–1148.
   PubMed Web of Science ®Google Scholar
• Rao M, Jaber BL, Balakrishnan VS. Inflammatory biomarkers and cardiovascular risk: association or cause and effect? Semin Dial 2006;19:129–135.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;3592195–2207.
   PubMed Web of Science ®Google Scholar
• Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983;34:141–212.
   PubMed Web of Science ®Google Scholar
• Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003;108:161–165.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557–1565.
   PubMed Web of Science ®Google Scholar
• Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109:1349–1353.
   PubMed Web of Science ®Google Scholar
• Guerrero-Romero F, Rodriguez-Moran M. Relation of C-reactive protein to features of the metabolic syndrome in normal glucose tolerant, impaired glucose tolerant, and newly diagnosed type 2 diabetic subjects. Diabetes Metab 2003;29:65–71.
   PubMed Web of Science ®Google Scholar
• Leinonen E, Hurt-Camejo E, Wiklund O, Hulten LM, Hiukka A, Taskinen MR. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003;166:387–394.
   PubMed Web of Science ®Google Scholar
• McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002;106:2908–2912.
   PubMed Web of Science ®Google Scholar
• Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42–47.
   PubMed Web of Science ®Google Scholar
• Aronson D, Sella R, Sheikh-Ahmad M, Kerner A, Avizohar O, Rispler S, Bartha P, Markiewicz W, Levy Y, Brook GJ. The association between cardiorespiratory fitness and C-reactive protein in subjects with the metabolic syndrome. J Am Coll Cardiol 2004;44:2003–2007.
   PubMed Web of Science ®Google Scholar
• Mojiminiyi OA, Abdella N, Moussa MA, Akanji AO, Al Mohammedi H, Zaki M. Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2002;58:37–44.
   PubMed Web of Science ®Google Scholar
• Niskanen L, Laaksonen DE, Nyyssonen K, Punnonen K, Valkonen VP, Fuentes R, Tuomainen TP, Salonen R, Salonen JT. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004;44:859–865.
   PubMed Web of Science ®Google Scholar
• Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens 2005;19:149–154.
   PubMed Web of Science ®Google Scholar
• Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, Murata C, Otsuka R, Zhu S, Toyoshima H. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 2003;27:443–449.
   PubMed Web of Science ®Google Scholar
• Fredrikson GN, Hedblad B, Nilsson JA, Alm R, Berglund G, Nilsson J. Association between diet, lifestyle, metabolic cardiovascular risk factors, and plasma C-reactive protein levels. Metabolism 2004;53:1436–1442.
   PubMed Web of Science ®Google Scholar
• Grau AJ, Buggle F, Becher H, Werle E, Hacke W. The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. Thromb Res 1996;82:245–255.
   PubMed Web of Science ®Google Scholar
• Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004;44:6–11.
   PubMed Web of Science ®Google Scholar
• Li JJ, Fang CH. Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis. Med Hypotheses 2004;63:100–102.
   PubMed Web of Science ®Google Scholar
• Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165–2168.
   PubMed Web of Science ®Google Scholar
• Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531–2534.
   PubMed Web of Science ®Google Scholar
• Verma S. Endothelin antagonism and insulin's vascular effects. Hypertension 2002;40:12–13.
   Web of Science ®Google Scholar
• Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992;4:361–368.
   PubMed Web of Science ®Google Scholar
• Woollard KJ, Phillips DC, Griffiths HR. Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clin Exp Immunol 2002;130:256–262.
   PubMed Web of Science ®Google Scholar
• Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002;99:13043–13048.
   PubMed Web of Science ®Google Scholar
• Frost F, Roach MJ, Kushner I, Schreiber P. Inflammatory C-reactive protein and cytokine levels in asymptomatic people with chronic spinal cord injury. Arch Phys Med Rehabil 2005;86:312–317.
   PubMed Web of Science ®Google Scholar
• Lang CH, Frost RA. Role of growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins in the catabolic response to injury and infection. Curr Opin Clin Nutr Metab Care 2002;5:271–279.
   PubMed Web of Science ®Google Scholar
• Milias GA, Nomikos T, Fragopoulou E, Athanasopoulos S, Antonopoulou S. Effects of eccentric exercise-induced muscle injury on blood levels of platelet activating factor (PAF) and other inflammatory markers. Eur J Appl Physiol 2005;95:504–513.
   PubMed Web of Science ®Google Scholar
• Banovac K, Sherman AL, Estores IM, Banovac F. Prevention and treatment of heterotopic ossification after spinal cord injury. J Spinal Cord Med 2004;27:376–382.
   PubMed Web of Science ®Google Scholar
• Estrores IM, Harrington A, Banovac K. C-reactive protein and erythrocyte sedimentation rate in patients with heterotopic ossification after spinal cord injury. J Spinal Cord Med 2004;27:434–437.
   PubMed Web of Science ®Google Scholar
• Manns PJ, McCubbin JA, Williams DP. Fitness, inflammation, and the metabolic syndrome in men with paraplegia. Arch Phys Med Rehabil 2005;86:1176–1181.
   PubMed Web of Science ®Google Scholar
• Wang TD, Wang YH, Huang TS, Su TC, Pan SL, Chen SY. Circulating levels of markers of inflammation and endothelial activation are increased in men with chronic spinal cord injury. J Formos Med Assoc 2007;106:919–928.
   PubMed Web of Science ®Google Scholar
• Liang H, Mojtahedi MC, Chen D, Braunschweig CL. Elevated C-reactive protein associated with decreased high-density lipoprotein cholesterol in men with spinal cord injury. Arch Phys Med Rehabil 2008;89:36–41.
   PubMed Web of Science ®Google Scholar
• Lee MY, Myers J, Hayes A, Madan S, Froelicher VF, Perkash I, Kiratli BJ. C-reactive protein, metabolic syndrome, and insulin resistance in individuals with spinal cord injury. J Spinal Cord Med 2005;28:20–25.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Morse LR, Stolzmann K, Nguyen HP, Jain NB, Zayac C, Gagnon DR, Tun CG, Garshick E. Association between mobility mode and C-reactive protein levels in men with chronic spinal cord injury. Arch Phys Med Rehabil 2008;89:726–731.
   PubMed Web of Science ®Google Scholar
• Nash MS, SL Gintel, AJ Mendez, LF Hamm, JE Lewis, SL Groah. Elevated CRP and vascular disease after SCI: inflammatory epiphenomenon or pathologic agent? J Spinal Cord Med 2006;29:252.
   Google Scholar
• Biasucci LM. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004;110:560–567.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–979.
   PubMed Web of Science ®Google Scholar
• Feng D, Tracy RP, Lipinska I, Murillo J, McKenna C, Tofler GH. Effect of short-term aspirin use on C-reactive protein. J Thromb Thrombolysis 2000;9:37–41.
   PubMed Web of Science ®Google Scholar
• Hooker SP, Wells CL. Effects of low- and moderate-intensity training in spinal cord-injured persons. Med Sci Sports Exerc 1989;21:18–22.
   PubMed Web of Science ®Google Scholar
• de Groot PC, Hjeltnes N, Heijboer AC, Stal W, Birkeland K. Effect of training intensity on physical capacity, lipid profile and insulin sensitivity in early rehabilitation of spinal cord injured individuals. Spinal Cord 2003;41:673–679.
   PubMed Web of Science ®Google Scholar
• El-Sayed MS, Younesian A. Lipid profiles are influenced by arm cranking exercise and training in individuals with spinal cord injury. Spinal Cord 2005;43:299–305.
   PubMed Web of Science ®Google Scholar
• Nash MS, Jacobs PL, Mendez AJ, Goldberg RB. Circuit resistance training improves the atherogenic lipid profiles of persons with chronic paraplegia. J Spinal Cord Med 2001;24:2–9.
   PubMedGoogle Scholar
• Dallmeijer AJ, Hopman MT, van der Woude LH. Lipid, lipoprotein, and apolipoprotein profiles in active and sedentary men with tetraplegia. Arch Phys Med Rehabil 1997;78:1173–1176.
   PubMed Web of Science ®Google Scholar
• Dallmeijer AJ, van der Woude LH, Hollander AP, van As HH. Physical performance during rehabilitation in persons with spinal cord injuries. Med Sci Sports Exerc 1999;31:1330–1335.
   PubMed Web of Science ®Google Scholar
• Janssen TW, van Oers CA, van Kamp GJ, TenVoorde BJ, van der Woude LH, Hollander AP. Coronary heart disease risk indicators, aerobic power, and physical activity in men with spinal cord injuries. Arch Phys Med Rehabil 1997;78:697–705.
   PubMed Web of Science ®Google Scholar
• Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, Macera CA, Heath GW, Thompson PD, Bauman A. Physical Activity and Public Health: updated Recommendation for Adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007;39:1423–1434.
   PubMed Web of Science ®Google Scholar
• Katsanos CS. Prescribing aerobic exercise for the regulation of postprandial lipid metabolism : current research and recommendations. Sports Med 2006;36:547–560.
   PubMed Web of Science ®Google Scholar
• Mestek ML, Plaisance EP, Ratcliff LA, Taylor JK, Wee SO, Grandjean PW. Aerobic exercise and postprandial lipemia in men with the metabolic syndrome. Med Sci Sports Exerc 2008;40:2105–2111.
   PubMed Web of Science ®Google Scholar
• Selvin E, Paynter NP, Erlinger TP. The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med 2007;167:31–39.
   PubMed Web of Science ®Google Scholar
• Plaisance EP, Grandjean PW. Physical activity and high-sensitivity C-reactive protein. Sports Med 2006;36:443–458.
   PubMed Web of Science ®Google Scholar
• Donnelly JE, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2009;41:459–471.
   PubMed Web of Science ®Google Scholar
• Abel T, Kroner M, Rojas VS, Peters C, Klose C, Platen P. Energy expenditure in wheelchair racing and handbiking – a basis for prevention of cardiovascular diseases in those with disabilities. Eur J Cardiovasc Prev Rehabil 2003;10:371–376.
   PubMedGoogle Scholar
• Laughton GE, Buchholz AC, Martin Ginis KA, Goy RE. Lowering body mass index cutoffs better identifies obese persons with spinal cord injury. Spinal Cord 2009;47:757–762.
   PubMed Web of Science ®Google Scholar
• Dufaux B, Order U, Geyer H, Hollmann W. C-reactive protein serum concentrations in well-trained athletes. Int J Sports Med 1984;5:102–106.
   PubMed Web of Science ®Google Scholar
• Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology 2002;13:561–568.
   PubMed Web of Science ®Google Scholar
• Pitsavos C, Chrysohoou C, Panagiotakos DB, Skoumas J, Zeimbekis A, Kokkinos P, Stefanadis C, Toutouzas PK. Association of leisure-time physical activity on inflammation markers (C-reactive protein, white cell blood count, serum amyloid A, and fibrinogen) in healthy subjects (from the ATTICA study). Am J Cardiol 2003;91:368–370.
   PubMed Web of Science ®Google Scholar
• Aronson D, Sheikh-Ahmad M, Avizohar O, Kerner A, Sella R, Bartha P, Markiewicz W, Levy Y, Brook GJ. C-Reactive protein is inversely related to physical fitness in middle-aged subjects. Atherosclerosis 2004;176:173–179.
   PubMed Web of Science ®Google Scholar
• Church TS, Barlow CE, Earnest CP, Kampert JB, Priest EL, Blair SN. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol 2002;22:1869–1876.
   PubMed Web of Science ®Google Scholar
• LaMonte MJ, Durstine JL, Yanowitz FG, Lim T, DuBose KD, Davis P, Ainsworth BE. Cardiorespiratory fitness and C-reactive protein among a tri-ethnic sample of women. Circulation 2002;106:403–406.
   PubMed Web of Science ®Google Scholar
• Isasi CR, Deckelbaum RJ, Tracy RP, Starc TJ, Berglund L, Shea S. Physical fitness and C-reactive protein level in children and young adults: the Columbia University BioMarkers Study. Pediatrics 2003;111:332–338.
   PubMed Web of Science ®Google Scholar
• Campbell PT, Campbell KL, Wener MH, Wood BL, Potter JD, McTiernan A, Ulrich CM. A yearlong exercise intervention decreases CRP among obese postmenopausal women. Med Sci Sports Exerc 2009;41:1533–1539.
   PubMed Web of Science ®Google Scholar
• Balducci S, Zanuso S, Massarini M, Corigliano G, Nicolucci A, Missori S, Cavallo S, Cardelli P, Alessi E, Pugliese G, Fallucca F. The Italian Diabetes and Exercise Study (IDES): design and methods for a prospective Italian multicentre trial of intensive lifestyle intervention in people with type 2 diabetes and the metabolic syndrome. Nutr Metab Cardiovasc Dis 200818585–595.
   PubMed Web of Science ®Google Scholar